Effects on bone mineral density of 12-month goserelin treatment in over 40-year-old women with uterine myomas

S. Bianchi, L. Fedele, M. Vignali, E. Galbiati, R. Cherubini, S. Ortolani

Research output: Contribution to journalArticlepeer-review

Abstract

We evaluated the effects on bone mineral density (BMD) of a 12-month treatment with goserelin depot, a gonadotropin-releasing hormone agonist, in a group of women with symptomatic uterine myomas requiring hysterectomy. Sixteen women, mean age 45.6±5.0, reporting menorrhagia associated with uterine myomas, candidates for hysterectomy, were scheduled to be treated with goserelin depot for 12 months. BMD was measured at the vertebral (L2-L4) and proximal femur level (femoral neck and trochanter) at the start of therapy and 6, 12, and 18 months later using dual energy X-ray absorptiometry (Hologic QDR 1000/W). The patients were followed for a minimum of 6 months after the end of treatment. Thirteen of the 16 women enrolled completed the treatment and three suspended it after 5, 6, and 7 months, respectively, because of side effects (hot flashes, insomnia, depression). Of the 13 women who completed the treatment, three underwent hysterectomy because of myoma regrowth and the recurrence of symptoms 3-18 months later; four reached the menopause 5-16 months later, and six were all menstruating normally with a follow-up varying from 6 to 18 months. After 12 months of therapy we observed a bone loss at vertebral, femoral neck, and trochanter of 4.4% (P

Original languageEnglish
Pages (from-to)78-80
Number of pages3
JournalCalcified Tissue International
Volume57
Issue number1
DOIs
Publication statusPublished - Jul 1995

Keywords

  • Bone loss
  • Goserelin
  • Uterine leiomyomata

ASJC Scopus subject areas

  • Endocrinology

Fingerprint

Dive into the research topics of 'Effects on bone mineral density of 12-month goserelin treatment in over 40-year-old women with uterine myomas'. Together they form a unique fingerprint.

Cite this